- Home
- SPCE vs IKT Comparison
SPCE vs IKT Comparison
Compare SPCE & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPCE | IKT |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.3M | 240.1M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SPCE | IKT |
|---|---|---|
| Price | $2.44 | $1.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $3.86 | ★ $5.50 |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 03-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.51 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,036,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,528.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.47 | N/A |
| 52 Week Low | $2.18 | $1.33 |
| 52 Week High | $5.59 | $2.46 |
Technical Indicators
Market Signals| Indicator | SPCE | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 40.49 | 41.97 |
| Support Level | $2.37 | $1.45 |
| Resistance Level | $2.67 | $1.79 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 11.86 | 14.10 |
Price Performance
Historical ComparisonAbout SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.